Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ALTO-101 by Alto Neuroscience for Cognitive Impairment Associated With Schizophrenia (CIAS): Likelihood of Approval
ALTO-101 is under clinical development by Alto Neuroscience and currently in Phase II for Cognitive Impairment Associated With Schizophrenia (CIAS)....